SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing downward pressure, sparking debates about a potential bear market and the influence of large traders. Community discussions range from disbelief and panic selling to calls for holding and buying the dip, with some pointing to historical cycles and technical indicators. The overall sentiment is mixed as participants grapple with the current volatility and speculate about future price movements.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending amid market volatility, with community members debating whether current price levels represent a buying opportunity or further downside. Discussions include speculation about institutional accumulation versus retail panic selling and the potential impact of upcoming upgrades. Some traders are expressing bearish sentiment and anticipating further drops, while others remain optimistic about Ethereum's long-term prospects.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing a selloff, with community members debating whether it's a bear trap or the start of a larger correction, possibly driven by concerns around Nvidia's upcoming earnings and their broader impact. The conversation also includes macro factors, potential Federal Reserve intervention, and comparisons to other global markets. Many are watching key support levels and VIX for directional clues.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending downwards as the price of ETH declines, causing concern among investors who discuss further potential drops and dilution. The community is debating whether to buy the dip or cut losses, with some questioning Tom Lee's influence and the company's management of its ETH treasury. Overall sentiment appears bearish amidst the current crypto market conditions.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amid a steep decline despite a recent announcement of a $250 million share repurchase program, leading to community debate on the effectiveness of the buyback and potential market manipulation. Discussions also involve the company's fundamentals, growth prospects, and the impact of Novo Nordisk's pricing on weight loss drugs. Some traders are anticipating a bounce, while others express bearish sentiment and suggest lower price targets.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the crypto market experiences volatility, leading to community debates about potential dips and buying opportunities. Discussions revolve around the impact of upcoming ETFs and ISO 20022 compliance, with some traders expressing concerns about market manipulation and others remaining optimistic about long-term gains. Sentiment is mixed, with some anticipating a price drop while others urge holding amid market fluctuations.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. is trending amid community discussions around potential financial strain and negative sentiment towards company leadership. Some traders are expressing concerns about the stock's long-term viability, while others allude to broader political and social issues surrounding the company's namesake.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

SGML is trending as traders actively discuss shorting opportunities, particularly around the 11 AM mark, citing chart patterns and perceived market tendencies. Some community members express bullish sentiment, pointing to the stock being undervalued compared to its peers and highlighting potential for a rebound in the lithium sector. Others remain skeptical, focusing on the stock's recent performance and expressing concerns about its current trajectory.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending downwards, sparking concerns about support levels and a potential return to previous lows, with some fearing a substantial drop. Despite strong October metrics and new features, community sentiment is largely negative, attributing the decline to broader market conditions and algorithmic trading. Some traders are speculating on a potential reversal, while others express frustration with the stock's performance and its correlation with Bitcoin.

Alpha Technology Group Ltd. is a holding company, which engages in the provision of cloud-based IT solution service. The company was founded by Leung Tsz Him on October 5, 2022 and is headquartered in Hong Kong.

Alpha Technology Group Ltd - Ordinary Shares - Class A

ALPHA TECHNOLOGY GROUP LTD

ATGL is experiencing significant volatility, with the community actively discussing its potential as a low-float runner and a possible short squeeze play. The stock's connection to Hong Kong-based entities and past instances of similar pumps are also fueling speculation and caution among traders. Overall, the conversation revolves around the stock's rapid price movement and the risks associated with its trading pattern.

statis crypto Watchlist

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CLDX &quot;Heads up alert! Only two days until Upcoming earnings on Monday, 11/3/2025 for $CLDX 
Bearish (2.5) 
 
In the analysis of Celldex Therapeutics (CLDX), recent developments indicate a challenging environment for the stock despite some positive clinical trial results. 
The company has reported initial favorable outcomes from a Phase 1 trial of CDX-622, showcasing a promising safety profile and effective mast cell inhibition. 
However, this positive momentum is overshadowed by Barclays&#39; recent initiation of coverage with an Underweight rating, raising concerns about the competitive landscape and safety issues surrounding its other product, barzolvolimab. 
This cautious outlook from a prominent financial institution has led to a notable decline in share price, reflecting investor sentiment that appears to be cautious at best. 
Financially, Celldex has demonstrated resilience with a one-year total shareholder return exceeding 15%, but the overall P/E ratio remains under scrutiny as analysts weigh its growth potential against industry benchmarks. 
Comparatively, Celldex&#39;s revenue forecasts and EPS growth are under pressure, particularly as competition intensifies within the biotech sector, which has seen a mix of performance among its peers. 
Regarding upcoming earnings reports, investors should be prepared for heightened scrutiny as analysts anticipate a clear picture of Celldex&#39;s financial health and operational execution. 
Historical performance suggests volatility around earnings announcements, especially following Barclays&#39; negative sentiment. 
Current consensus estimates point to a cautious outlook, and any deviation from expectations could significantly impact the stock&#39;s trajectory. 
The market will be keenly observing not only the financial metrics but also any updates on ongoing clinical trials that could influence future revenue streams. 
In terms of sector performance, the biotechnology field has experienced mixed results this year, with some companies thriving on innovative therapies while others, like Celldex, grapple with investor skepticism. 
The overall sentiment in the biotech sector remains cautious, reflecting broader economic conditions and specific challenges faced by companies in clinical development phases. 
 
- Funds were net sellers of $CLDX during the previous reporting quarter. 
 
- Funds with large holdings in $CLDX include: 
 
- Eventide Asset Management, MV: $28MM. Fund Rank: 58% 
 
- Baker Brothers Advisors LP, MV: $14MM. Fund Rank: 71% 
 
- Last 10 days performance: 0% 
- Last 30 days performance: 3% 
- Last 90 days performance: 20% 
 
Some of the latest news articles: 
 - Title: Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition 
Publication Date: 10/30/2025 8:01:00 PM, Source: yahoo 
URL: https://finance.yahoo.com/news/celldex-announces-initial-positive-results-200100892.html?.tsrc=rss 
 
 - Title: Celldex Therapeutics (CLDX): Evaluating Valuation After Barclays&#39; Underweight Rating and Industry Concerns 
Publication Date: 10/23/2025 6:12:50 AM, Source: yahoo 
URL: https://finance.yahoo.com/news/celldex-therapeutics-cldx-evaluating-valuation-061250034.html?.tsrc=rss 
 
 - Title: Barclays Initiates Coverage of Celldex Therapeutics (CLDX) With an Underweight Rating 
Publication Date: 10/21/2025 3:08:35 AM, Source: yahoo 
URL: https://finance.yahoo.com/news/barclays-initiates-coverage-celldex-therapeutics-030835531.html?.tsrc=rss 
 
 - Title: Barclays initiates coverage on U.S. small &amp; mid-cap biotech stocks 
Publication Date: 10/13/2025 9:52:36 AM, Source: yahoo 
URL: https://finance.yahoo.com/news/barclays-initiates-coverage-u-small-095236805.html?.tsrc=rss 
 
Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal.&quot;

Data from Phase 1 Study in healthy volunteers presented at CIA Biennial Symposium-- HAMPTON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today positive data from the ongoing Phase 1 study of CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosis-mast cell depletion via stem cell factor (SCF) starvation and neutralization of the alarmin thymic stromal lymphopoietin (TSLP).

Yahoo Finance

Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition

Barclays' recent launch of coverage on Celldex Therapeutics (CLDX) assigned the stock an Underweight rating, drawing investor focus to both sector competition and questions about the safety profile of barzolvolimab. See our latest analysis for Celldex Therapeutics. After Barclays' cautious initiation, Celldex's share price dipped over 4% in a day.

Celldex Therapeutics (CLDX): Evaluating Valuation After Barclays' Underweight Rating and Industry Concerns

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the best small cap stocks with the highest upside. Barclays initiated coverage of Celldex Therapeutics, Inc. (NASDAQ:CLDX) with an Underweight rating on October 13, assigning a $25 price target to the shares. The rating came as part of the firm's launch of eight companies across rare diseases, inflammation [...]

Barclays Initiates Coverage of Celldex Therapeutics (CLDX) With an Underweight Rating

Investing.com -- Momentum in small and mid-cap (SMID) biotechnology has accelerated recently, with investors rewarding companies bringing new mechanisms and dosing advantages to market.

Barclays initiates coverage on U.S. small & mid-cap biotech stocks

Stocktwits provides real-time stock, crypto & international market data to keep you up-to-date. Find top news headlines, discover your next trade idea, share & gain insights from traders and investors from around the world, build a watchlist, buy US stocks, & create and manage your portfolio.

Stocktwits

Stocktwits - Stock Market Live Quotes, Social Community Discussions, News, Stock Rankings & Earnings

StockTwits Web

Celldex Therapeutics Inc.

 "Heads up alert! Only two days until Upcoming earnings on Monday, 11/3/2025 for 

 
Bearish (2.5) 
 
In the analysis of Celldex Therapeutics (CLDX), recent developments indicate a challenging environment for the stock despite some positive clinical trial results. 
The company has reported initial favorable outcomes from a Phase 1 trial of CDX-622, showcasing a promising safety profile and effective mast cell inhibition. 
However, this positive momentum is overshadowed by Barclays' recent initiation of coverage with an Underweight rating, raising concerns about the competitive landscape and safety issues surrounding its other product, barzolvolimab. 
This cautious outlook from a prominent financial institution has led to a notable decline in share price, reflecting investor sentiment that appears to be cautious at best. 
Financially, Celldex has demonstrated resilience with a one-year total shareholder return exceeding 15%, but the overall P/E ratio remains under scrutiny as analysts weigh its growth potential against industry benchmarks. 
Comparatively, Celldex's revenue forecasts and EPS growth are under pressure, particularly as competition intensifies within the biotech sector, which has seen a mix of performance among its peers. 
Regarding upcoming earnings reports, investors should be prepared for heightened scrutiny as analysts anticipate a clear picture of Celldex's financial health and operational execution. 
Historical performance suggests volatility around earnings announcements, especially following Barclays' negative sentiment. 
Current consensus estimates point to a cautious outlook, and any deviation from expectations could significantly impact the stock's trajectory. 
The market will be keenly observing not only the financial metrics but also any updates on ongoing clinical trials that could influence future revenue streams. 
In terms of sector performance, the biotechnology field has experienced mixed results this year, with some companies thriving on innovative therapies while others, like Celldex, grapple with investor skepticism. 
The overall sentiment in the biotech sector remains cautious, reflecting broader economic conditions and specific challenges faced by companies in clinical development phases. 
 
- Funds were net sellers of 

 during the previous reporting quarter. 
 
- Funds with large holdings in 

 include: 
 
- Eventide Asset Management, MV: $28MM. Fund Rank: 58% 
 
- Baker Brothers Advisors LP, MV: $14MM. Fund Rank: 71% 
 
- Last 10 days performance: 0% 
- Last 30 days performance: 3% 
- Last 90 days performance: 20% 
 
Some of the latest news articles: 
 - Title: Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition 
Publication Date: 10/30/2025 8:01:00 PM, Source: yahoo 
URL: 

 
 
 - Title: Celldex Therapeutics (CLDX): Evaluating Valuation After Barclays' Underweight Rating and Industry Concerns 
Publication Date: 10/23/2025 6:12:50 AM, Source: yahoo 
URL: 

 
 
 - Title: Barclays Initiates Coverage of Celldex Therapeutics (CLDX) With an Underweight Rating 
Publication Date: 10/21/2025 3:08:35 AM, Source: yahoo 
URL: 

 
 
 - Title: Barclays initiates coverage on U.S. small & mid-cap biotech stocks 
Publication Date: 10/13/2025 9:52:36 AM, Source: yahoo 
URL: 

 for more earnings alerts. Not a financial advice. Not a trading signal."